Gate Stock Token April Latest Updates: Contract Launches, Feature Upgrades, and Popular Assets

robot
Abstract generation in progress

In the first quarter of 2026, Gate’s Contracts Stock section saw multiple rounds of new listings. As of April 9, Gate has added and launched over 30 perpetual contract products for stocks and ETFs throughout 2026, covering multiple segments including technology giants, leading companies in aerospace and defense, consumer goods giants, and core ETFs:

  • January 29: The first batch of 10 US stock perpetual contracts was launched, including MSFT (Microsoft), IBM, INTC (Intel), MCD (McDonald’s), CSCO (Cisco), ASML (ASML), LLY (Eli Lilly), MRVL (Marvell Technology), UNH (UnitedHealth Group), and ARM (Arm). The contracts are settled in USDT and support long/short trading with leverage of 1–20x.
  • January 30: Immediately following, 11 token-based perpetual contract trading pairs were launched, including PEP (PepsiCo), GE (GE Aerospace), AVGO (Broadcom), IAU (iShares Gold Trust), PG (Procter & Gamble), KO (Coca-Cola), LMT (Lockheed Martin), AMD (Advanced Micro Devices), IEFA (iShares MSCI EAFE ETF), TLT (iShares 20+ Year Treasury Bond ETF), and AGG (iShares Core US Aggregate Bond ETF).
  • February 6: MU (Micron Technology), COHR (Coherent), and LITE (Lumintop) perpetual contracts were launched, enriching tradable targets in the technology segment.
  • March 3: Gate launched the first global real-trading listings for perpetual contracts including RTX (Raytheon), GD (General Dynamics), NOC (Northrop Grumman), BA (Boeing), TSM (TSMC), WMT (Walmart), and COST (Costco). They are settled in USDT and support leverage of 1–20x. On the same day, Gate’s Index section simultaneously launched the first real-trading listing of GER40 (Germany DAX 40 Index) perpetual contracts, expanding tradable targets from individual stocks to core market indices.
  • March 4: SNDK (SanDisk) perpetual contract real trading was launched.

With a dense rollout of new products, the selection of underlying assets in Gate’s Contracts Stock section has become more diverse, giving traders with preferences across different sectors more varied leverage trading options.

Product feature upgrade: from a single trading experience to a multi-asset integrated trading system

In early 2026, Gate officially completed a major upgrade of its TradFi (traditional finance) products, achieving full coverage across both mobile and web platforms. The core logic behind this upgrade is to build a multi-asset integrated trading system. With this upgrade, users can trade CFD (contracts for difference) products for stock tokens, forex, precious metals, indices, and commodities all within the same platform, further reducing operational friction in cross-market allocation.

In addition, Gate’s stock token product line has expanded from the initial xStocks to a dual-product architecture running xStocks and Ondo Stocks in parallel. Both adopt a full-collateral model, maintain a 1:1 peg to real stock prices, and support nonstop trading 24/7. According to official data, as of early 2026, Gate’s stock token section has surpassed $140 billion in cumulative trading volume, with a monthly market share as high as 89.1%.

Summary

Since 2026, Gate’s stock token product line has continued to iterate, showing significant progress in expanding contract underlying assets, upgrading trading functions, optimizing assets, and covering popular underlyings. Whether you are a contracts trader who prefers leverage trading, or a spot investor looking to allocate globally high-quality assets for the long term, Gate’s stock token section offers you more diversified trading choices. For more the latest updates, please follow Gate’s official announcements.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments